Finding the origins of infant leukaemia

October 15, 2012
Finding the origins of infant leukaemia
Credit: Thinkstock

Leukaemia arises as a result of genetic or epigenetic alterations in blood cells, leading to an aberrant accumulation of undifferentiated blasts. Understanding the molecular pathogenesis and aetiology of infant leukaemia induced by the MLL-AF4 fusion gene was the subject of the Leukaemogenesis project.

The mixed lineage leukaemia (MLL) gene is one of the most frequently mutated genes in infant acute leukaemias, leading to fusions that involve more than 50 different partners. Detection of MLL translocations at diagnosis is a strong negative of the disease.

In infant acute lymphoblastic leukaemia (ALL), MLL-AF4 is very common and arises in utero. However, very little is known about the nature of the that becomes transformed in the embryo and the mechanisms accounting for its B cell lineage affiliation.

Although various murine models for MLL leukaemias exist, they fail to replicate many of the features of the human disease, suggesting that there are essential steps during early human development required for leukaemia onset. Seeking to address this issue, the EU Leukaemogenesis project was designed to determine the that was most vulnerable to transformation by the MLL-AF4 gene.

As a first approach, scientists explored the in vitro and in vivo developmental impact of MLL-AF4 expression on haematopoietic stem progenitor cells (HSPCs) isolated from umbilical cord blood. MLL-AF4 seemed to augment the proliferation, clonogenic potential and in vivo multilineage haematopoietic engraftment of HSPCs. However, it was not sufficient to induce leukaemogenesis on its own, indicating that either additional hits were required to develop leukaemia or these cells were the inappropriate target.

In a similar way, MLL-AF4 expression was not sufficient to transform haematopoietic cells differentiated from human (hESC). Interestingly, a reduced production of haematopoietic cells was observed concomitant with an enhanced mature endothelial cell fate, suggesting that MLL-AF4 skewed the potential of common haemato-endothelial precursors towards a pronounced endothelial cell fate.

Scientists are hopeful that the precise mechanism of MLL-AF4–mediated cell transformation would be addressed by studying induced pluripotent stem cells (iPSCs) from infant patient blasts. Nonetheless, the platform generated during the Leukaemogenesis project constitutes an important tool for studying cellular and molecular mechanisms during early embryonic development and could be further utilised for drug screening and toxicity.

Explore further: Stem cell treatment to prevent leukemia returning is a step closer, say scientists

Related Stories

Stem cell treatment to prevent leukemia returning is a step closer, say scientists

June 2, 2011
Researchers at King's College London have identified a way of eliminating leukaemic stem cells, which could lead to new treatments that may enable complete remission for leukaemia patients. An early study in mice has shown ...

Possible new approach to treating deadly leukemia in babies

April 13, 2011
A Loyola University Health System study points to a promising new approach to treating an aggressive and usually fatal leukemia in babies.

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.